tiprankstipranks
Trending News
More News >
Craneware Plc (GB:CRW)
LSE:CRW

Craneware (CRW) AI Stock Analysis

Compare
18 Followers

Top Page

GB

Craneware

(LSE:CRW)

Rating:69Neutral
Price Target:
2,420.00p
▲(18.63%Upside)
Craneware's overall stock score reflects strong financial performance and positive corporate events. However, the high valuation and bearish technical indicators weigh on the score. The company's robust profitability and strategic advancements are significant strengths, while the technical downtrend and high P/E ratio present short-term challenges.

Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)

Craneware Business Overview & Revenue Model

Company DescriptionCraneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; integration for chargemaster management, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits. In addition, the company provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; trisus pricing transparency; InSight Denials to analyze, track, trend, and report on denial data; and appeals services. Further, it offers customer success management and consulting services; professional services; and sales and marketing, and product and software development services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
How the Company Makes MoneyCraneware makes money primarily through the sale of its software solutions, which are provided on a subscription basis. The company's revenue model is largely based on recurring revenue from its software-as-a-service (SaaS) offerings, which provide healthcare organizations with tools for revenue cycle and value cycle management. Key revenue streams include subscription fees, software licenses, and professional services such as implementation and consulting. Significant partnerships with healthcare providers and institutions further contribute to its earnings, as these collaborations help expand its customer base and drive adoption of its solutions.

Craneware Financial Statement Overview

Summary
Craneware exhibits strong financial performance with solid revenue growth, efficient operations, and a stable balance sheet. The company maintains strong cash flow generation, though net profit margins and free cash flow growth could be improved. Overall, Craneware's financial health is solid.
Income Statement
85
Very Positive
Craneware demonstrated strong revenue growth of 8.77% from 2023 to 2024, with a solid gross profit margin of 85.7% and a net profit margin of 6.2% in 2024. The EBIT margin was 10.4%, indicating efficient operations, while the EBITDA margin of 28.7% reflects healthy cash generation from operations. Overall, the company shows robust profitability and growth, although net profit margins could be improved.
Balance Sheet
80
Positive
The debt-to-equity ratio improved significantly, reflecting a strong balance sheet with a lower debt burden. Return on equity is moderate at 3.6%, indicating room for improvement in asset utilization. The equity ratio is a healthy 60.4%, suggesting financial stability. The balance sheet shows prudent financial management with a focus on maintaining low leverage.
Cash Flow
78
Positive
Free cash flow decreased from 2023 to 2024, but the company maintains a solid operating cash flow to net income ratio of 3.6, highlighting efficient cash generation relative to earnings. The free cash flow to net income ratio is favorable, showing a strong conversion of earnings into cash. The company should focus on improving free cash flow growth to enhance financial flexibility.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
198.10M189.27M174.02M165.54M75.58M71.49M
Gross Profit
171.02M162.20M148.44M142.37M70.20M66.97M
EBIT
22.31M19.73M19.23M18.13M13.24M19.21M
EBITDA
36.65M54.26M51.60M47.54M18.48M24.06M
Net Income Common Stockholders
14.88M11.70M9.23M9.41M12.90M16.84M
Balance SheetCash, Cash Equivalents and Short-Term Investments
72.16M34.59M78.54M47.16M235.62M47.85M
Total Assets
565.96M543.65M576.98M568.79M311.60M115.76M
Total Debt
35.89M40.15M86.69M113.08M1.15M2.02M
Net Debt
-36.27M5.56M8.15M65.93M-234.47M-45.83M
Total Liabilities
236.84M215.06M249.13M235.77M51.32M47.36M
Stockholders Equity
329.12M328.59M327.84M333.02M260.28M68.39M
Cash FlowFree Cash Flow
68.61M24.91M83.20M12.93M13.21M10.96M
Operating Cash Flow
69.53M41.86M98.75M26.96M23.54M20.67M
Investing Cash Flow
-14.27M-15.81M-15.34M-307.32M-10.32M-9.71M
Financing Cash Flow
-46.99M-70.00M-53.28M91.90M174.55M-10.72M

Craneware Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2040.00
Price Trends
50DMA
1842.40
Positive
100DMA
1871.86
Positive
200DMA
1997.99
Positive
Market Momentum
MACD
50.50
Positive
RSI
50.93
Neutral
STOCH
21.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Neutral. The current price of 2040 is below the 20-day moving average (MA) of 2076.25, above the 50-day MA of 1842.40, and above the 200-day MA of 1997.99, indicating a neutral trend. The MACD of 50.50 indicates Positive momentum. The RSI at 50.93 is Neutral, neither overbought nor oversold. The STOCH value of 21.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:CRW.

Craneware Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBSPI
74
Outperform
£840.96M33.173.41%1.10%11.20%-6.80%
GBAMS
72
Outperform
£461.60M64.652.93%1.14%40.66%-55.09%
GBCRW
69
Neutral
£721.40M61.824.50%1.43%6.74%54.83%
65
Neutral
£333.86M8.5411.74%38.80%
GBONT
61
Neutral
£1.15B-23.77%7.97%12.94%
GBAPH
59
Neutral
$355.92M-5.04%-1.02%67.70%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:CRW
Craneware
2,005.00
-351.59
-14.92%
GB:AMS
Advanced Medical Solutions
215.00
-3.23
-1.48%
GB:APH
Alliance Pharma
64.70
30.30
88.08%
GB:PRTC
PureTech Health
139.80
-85.20
-37.87%
GB:SPI
Spire Healthcare
208.00
-34.14
-14.10%
GB:ONT
Oxford Nanopore Technologies PLC
123.90
21.00
20.41%

Craneware Corporate Events

M&A Transactions
Craneware plc Faces Potential Acquisition by Bain Capital
Neutral
May 16, 2025

Craneware plc has announced that Bain Capital Private Equity is assessing a possible offer for the company. While no formal proposal has been received, Bain Capital has until June 13, 2025, to announce its intentions. This potential offer could significantly impact Craneware’s market positioning and stakeholder interests, pending further developments.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Business Operations and Strategy
Craneware Sees Shift in Major Shareholder Voting Rights
Neutral
May 1, 2025

Craneware plc has announced a change in its major holdings, with Liontrust Investment Partners LLP adjusting its voting rights in the company. The adjustment reflects a decrease in Liontrust’s total voting rights from 10.977% to 10.1601%, indicating a strategic shift in their investment stance. This change may impact the company’s shareholder dynamics and influence future corporate decisions.

Executive/Board ChangesRegulatory Filings and Compliance
Craneware Chair Increases Stake Amid Voting Rights Adjustment
Positive
Apr 28, 2025

Craneware plc announced that its Chair, Will Whitehorn, purchased 1,911 Ordinary Shares, reflecting a minor increase in his stake in the company. This transaction highlights confidence in Craneware’s market position and could positively influence stakeholder perception. Additionally, the company adjusted its total voting rights following the transfer of shares to satisfy employee share options, which now stands at 35,409,802 shares with voting rights.

Dividends
Craneware Announces Interim Dividend Details and Currency Election
Positive
Mar 21, 2025

Craneware plc, a prominent provider of healthcare financial performance solutions, announced details regarding its interim dividend payment. Shareholders who opted for the US dollar payment will receive their dividends at an exchange rate of $1.30. This announcement reflects Craneware’s commitment to providing flexible financial options to its shareholders, potentially impacting its market positioning by enhancing shareholder satisfaction.

Business Operations and StrategyFinancial Disclosures
Craneware Achieves Record Interim Results with Double-Digit Growth
Positive
Mar 11, 2025

Craneware plc has reported record interim financial results for the first half of FY25, with a notable return to double-digit growth rates. The company’s revenue exceeded $100 million, driven by expansion with existing customers and new customer acquisitions. The strong financial performance is underpinned by high levels of annual recurring revenue and customer retention. Craneware’s strategic partnership with Microsoft has led to significant advancements in AI-enhanced offerings, including the launch of Trisus® Assist, an AI-powered personal assistant. The company continues to invest in R&D and innovation, strengthening its market position and supporting its ambitious growth strategy. The outlook remains positive, with expectations of sustained demand from US hospitals focusing on strategic growth post-election.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.